These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 27318707)

  • 21. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
    Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease.
    Zibetti M; Angrisano S; Dematteis F; Artusi CA; Romagnolo A; Merola A; Lopiano L
    J Neurol Sci; 2018 Feb; 385():105-108. PubMed ID: 29406886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A
    Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Artificial Neural Network Predicts Gender Differences of Motor and Non-Motor Symptoms of Patients with Advanced Parkinson's Disease under Levodopa-Carbidopa Intestinal Gel.
    Bougea A; Derikvand T; Efthimiopoulou E
    Medicina (Kaunas); 2024 May; 60(6):. PubMed ID: 38929490
    [No Abstract]   [Full Text] [Related]  

  • 27. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
    Chaudhuri KR; Pickard AS; Alobaidi A; Jalundhwala YJ; Kandukuri PL; Bao Y; Sus J; Jones G; Ridley C; Oddsdottir J; Najle-Rahim S; Madin-Warburton M; Xu W; Schrag A
    Pharmacoeconomics; 2022 May; 40(5):559-574. PubMed ID: 35307793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
    Fabbri M; Pongmala C; Artusi CA; Romagnolo A; Rizzone MG; Zibetti M; Lopiano L
    Acta Neurol Scand; 2019 Aug; 140(2):157-161. PubMed ID: 31025312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study].
    Skoromets AA; Odinak MM; Yakupov EZ; Litvinenko IV; Zalyalova ZA; Timofeeva AA; Kirtaev SY; Bogdanov RR; Agafina AS; Chatamra K; Robieson W; Benesh J; Latypova GR; Ershova MV; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):22-31. PubMed ID: 28374689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
    Antonini A; Marano P; Gusmaroli G; Modugno N; Pacchetti C; Sensi M; Melzi G; Bergmann L; Zibetti M; Lopiano L
    Neurol Sci; 2020 Oct; 41(10):2929-2937. PubMed ID: 32342325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
    Blaise AS; Baille G; Carrière N; Devos D; Dujardin K; Grolez G; Kreisler A; Kyheng M; Moreau C; Mutez E; Seguy D; Defebvre L
    Rev Neurol (Paris); 2020 May; 176(4):268-276. PubMed ID: 31668287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland.
    Weiss D; Ebersbach G; Möller JC; Schwarz J; Arlt C; Fritz B; Sensken SC; Eggert K
    Parkinsonism Relat Disord; 2022 Oct; 103():85-91. PubMed ID: 36087571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study.
    Moes HR; Groenendal-Laurensse JWMJ; Drent M; Tissingh G; van Laar T
    J Parkinsons Dis; 2020; 10(3):935-944. PubMed ID: 32675420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
    Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
    Fernandez HH; Vanagunas A; Odin P; Espay AJ; Hauser RA; Standaert DG; Chatamra K; Benesh J; Pritchett Y; Hass SL; Lenz RA
    Parkinsonism Relat Disord; 2013 Mar; 19(3):339-45. PubMed ID: 23287001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review.
    Zhang XR; Jiang ZY; Zhang ZR; Chen HJ; Wu K; He JC; Xie CL
    Drug Des Devel Ther; 2020; 14():845-854. PubMed ID: 32161444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
    Fabbri M; Zibetti M; Beccaria L; Merola A; Romagnolo A; Montanaro E; Ferreira JJ; Palermo S; Lopiano L
    Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.